Published in Lung Cancer Manag on December 01, 2012
LRIG2 expression and prognosis in non-small cell lung cancer. Oncol Lett (2014) 0.86
Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma. BMC Bioinformatics (2016) 0.81
Exploring estrogenic activity in lung cancer. Mol Biol Rep (2016) 0.77
Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.77
Association between the CYP11 family and six cancer types. Oncol Lett (2016) 0.75
Survival in women with NSCLC: the role of reproductive history and hormone use. J Thorac Oncol (2014) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. Br Med J (1956) 16.29
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health (1978) 7.80
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol (1999) 3.74
Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer (2012) 3.55
Lung cancer incidence in never smokers. J Clin Oncol (2007) 3.20
Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol (2005) 2.88
Production and actions of estrogens. N Engl J Med (2002) 2.66
The effect of age at smoking initiation on lung cancer risk. Epidemiology (1993) 2.59
Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res (2002) 2.52
Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat (1999) 2.30
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer (2001) 2.23
Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. N Engl J Med (1979) 2.19
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Progestin regulation of cellular proliferation. Endocr Rev (1990) 2.04
Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer (2004) 1.84
Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol (2002) 1.83
Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids (2007) 1.80
Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev (2005) 1.75
Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res (2005) 1.73
Lung cancer in US women: a contemporary epidemic. JAMA (2004) 1.70
Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun (2001) 1.67
Estrogen receptor beta--a new dimension in estrogen mechanism of action. J Endocrinol (1999) 1.64
Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol (2007) 1.62
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60
Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res (2005) 1.59
Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res (2004) 1.57
Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids (2005) 1.57
Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg (2003) 1.56
Aromatase inhibitors in human lung cancer therapy. Cancer Res (2005) 1.55
The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg (2005) 1.55
Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res (2007) 1.54
Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy. Cancer Res (2005) 1.51
Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol (2003) 1.44
Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res (2005) 1.40
Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci (2009) 1.39
Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res (2012) 1.34
Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer (2008) 1.34
The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. JAMA (1973) 1.34
Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res (2008) 1.33
Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol (2008) 1.32
Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer (2007) 1.32
Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst (2010) 1.31
Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol (2010) 1.30
Estrogens as regulators of bone health in men. Nat Rev Endocrinol (2009) 1.26
Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res (2007) 1.24
Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer (2006) 1.24
Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.24
Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol (2009) 1.22
Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res (1991) 1.21
Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med (2010) 1.19
Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors. FASEB J (2000) 1.17
Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res (2010) 1.17
Estrogen receptor pathways in lung cancer. Curr Oncol Rep (2004) 1.15
Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer (1996) 1.13
The epidemiology of lung cancer. Ann Oncol (1999) 1.12
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer (2008) 1.11
Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer (2010) 1.11
Epidemiology of lung cancer in women: risk factors, survival, and screening. AJR Am J Roentgenol (2011) 1.10
Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol (2006) 1.05
Relationship between cigarette smoking and histological type of lung cancer in women. Thorax (1973) 1.04
Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab (1994) 1.02
Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol (2009) 1.01
Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol Endocrinol (2012) 1.01
Early changes in gene expression induced by tobacco smoke: Evidence for the importance of estrogen within lung tissue. Cancer Prev Res (Phila) (2010) 1.01
Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer (2011) 1.00
Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res (1997) 0.99
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids (2011) 0.98
Estrogen receptor-alpha regulates pulmonary alveolar loss and regeneration in female mice: morphometric and gene expression studies. Am J Physiol Lung Cell Mol Physiol (2007) 0.97
Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol (2009) 0.96
Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg (2011) 0.95
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer (2011) 0.94
Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol (2011) 0.93
Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol (2006) 0.93
Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol (1997) 0.92
Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer (2009) 0.92
Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab (2011) 0.92
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. Am J Respir Cell Mol Biol (2009) 0.91
Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol (2009) 0.91
Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol (2009) 0.90
Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother (2009) 0.90
Sex steroid receptors in human lung diseases. J Steroid Biochem Mol Biol (2011) 0.89
Estrogen acutely stimulates endothelial nitric oxide synthase in H441 human airway epithelial cells. Am J Respir Cell Mol Biol (1999) 0.88
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. Cancer Res (2010) 0.87
Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg (2002) 0.86
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis (2012) 0.86
Chasing mutations in the epidermal growth factor in lung cancer. N Engl J Med (2005) 0.85
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res (2006) 2.47
Global levels of histone modifications predict prognosis in different cancers. Am J Pathol (2009) 2.28
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids (2007) 1.80
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 1.66
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol (2006) 1.60
Aromatase inhibitors in human lung cancer therapy. Cancer Res (2005) 1.55
Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res (2007) 1.54
Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat (2007) 1.54
Identification of genes differentially expressed in rat alveolar type I cells. Am J Respir Cell Mol Biol (2004) 1.49
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res (2004) 1.46
Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res (2010) 1.44
Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res (2009) 1.43
Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res (2013) 1.41
Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J Biol Chem (2005) 1.39
Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci (2009) 1.39
Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol (2005) 1.37
Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol (2010) 1.28
Genetic differences in human circadian clock genes among worldwide populations. J Biol Rhythms (2008) 1.27
Shift work in nurses: contribution of phenotypes and genotypes to adaptation. PLoS One (2011) 1.25
Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res (2004) 1.25
Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res (2007) 1.24
COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J (2003) 1.24
Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res (2007) 1.23
Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics (2009) 1.19
Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer (2008) 1.17
The tetraspan protein epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesion. J Biol Chem (2002) 1.16
Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer (2010) 1.16
Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res (2011) 1.15
Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci U S A (2005) 1.14
The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins. Mol Biol Cell (2004) 1.13
Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol (2003) 1.12
A metaproteomic approach to study human-microbial ecosystems at the mucosal luminal interface. PLoS One (2011) 1.12
Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium. Dev Biol (2005) 1.12
Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics (2011) 1.12
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res (2008) 1.08
FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Invest Ophthalmol Vis Sci (2008) 1.06
RIN1 is a breast tumor suppressor gene. Cancer Res (2007) 1.05
Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat (2005) 1.05
Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res (2006) 1.05
Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol (2006) 1.05
Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem Biophys Res Commun (2005) 1.04
The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death. Clin Immunol (2003) 1.04
Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene (2002) 1.03
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids (2011) 0.98
Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem (2003) 0.98
Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface. Inflamm Bowel Dis (2011) 0.97
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer (2011) 0.94
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer (2011) 0.94
Elevated MED28 expression predicts poor outcome in women with breast cancer. BMC Cancer (2010) 0.94
Uncertainty and psychological adjustment in patients with lung cancer. Psychooncology (2012) 0.93
Identification of candidate microbial sequences from inflammatory lesion of giant cell arteritis. Clin Immunol (2004) 0.92
Epithelial membrane protein 2 modulates infectivity of Chlamydia muridarum (MoPn). Microbes Infect (2007) 0.91
IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun (2005) 0.91
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol (2013) 0.91
Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol (2013) 0.90
Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. Cancer (2010) 0.90
Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. Cancer Biomark (2009) 0.89
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol (2012) 0.89
Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2). Invest Ophthalmol Vis Sci (2009) 0.89
Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin Cancer Res (2010) 0.89
Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src. PLoS One (2011) 0.89
New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat (2005) 0.89
Protein expression based multimarker analysis of breast cancer samples. BMC Cancer (2011) 0.88
Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res (2013) 0.88
Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood (2006) 0.87
Antiangiogenic Steroids in Human Cancer Therapy. Evid Based Complement Alternat Med (2005) 0.87
Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate (2003) 0.85
Estrogen receptors and cell signaling. Science (2005) 0.85
PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res (2014) 0.84
BetaB1-crystallin: identification of a candidate ciliary body uveitis antigen. Invest Ophthalmol Vis Sci (2003) 0.84
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol (2013) 0.84
Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta. Int J Oncol (2004) 0.83
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway. J Pathol (2014) 0.83
Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther (2014) 0.83
Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol (2012) 0.82
The new staging system for lung cancer: imaging and clinical implications. J Thorac Imaging (2011) 0.81
Peripheral myelin protein-22 (PMP22) modulates alpha 6 integrin expression in the human endometrium. Reprod Biol Endocrinol (2011) 0.80
One-step RT-PCR for screening microdissected tissue samples. Biotechniques (2002) 0.79
Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer. Am J Physiol Lung Cell Mol Physiol (2012) 0.79
High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation. J Cardiothorac Surg (2011) 0.77
Direct electronic detection of prostate-specific antigen in serum. Small (2007) 0.76
Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancer. Chest (2004) 0.76
Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. Mod Pathol (2012) 0.76
Management of small-cell lung cancer: time to move forward. Oncology (Williston Park) (2010) 0.75
Overview of the FASEB 2004 summer research conference on steroid hormone receptors: integration of plasma membrane and nuclear-initiated signaling in hormone action. Steroids (2005) 0.75
Proapoptotic agents in lung cancer. J Thorac Oncol (2010) 0.75